Global trial to find effective treatments for stroke
A Multi-faCtorial, mulTi-arm, Multi-staGe, Randomised, gLOBal Adaptive pLatform Trial for Stroke (ACT-GLOBAL)
PHASE3 · The George Institute · NCT06352632
This study is testing different treatments for stroke patients to see which ones work best to improve their recovery.
Quick facts
| Phase | PHASE3 |
|---|---|
| Study type | Interventional |
| Enrollment | 20000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | The George Institute (other) |
| Locations | 2 sites (Sydney, New South Wales and 1 other locations) |
| Trial ID | NCT06352632 on ClinicalTrials.gov |
What this trial studies
ACT-GLOBAL is a multi-factorial, multi-arm, multi-stage adaptive platform trial designed to identify the most effective treatments for stroke patients. The trial evaluates various interventions, including different doses of intravenous tenecteplase and blood pressure control strategies, to determine their impact on patient outcomes. By conducting frequent adaptive analyses, the study aims to assess the efficacy of these treatments in real-time, allowing for adjustments based on accumulating data. This innovative approach seeks to address the urgent need for improved stroke interventions that can be widely applied.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 years and older who have been clinically diagnosed with a stroke.
Not a fit: Patients who do not have a clinical diagnosis of stroke or are under 18 years old may not benefit from this study.
Why it matters
Potential benefit: If successful, this trial could lead to more effective treatment options for stroke patients, potentially reducing mortality and disability rates.
How similar studies have performed: Other adaptive platform trials have shown promise in identifying effective treatments for various conditions, suggesting that this approach could yield valuable insights for stroke management.
Eligibility criteria
Show full inclusion / exclusion criteria
Platform Inclusion Criteria: 1. Age ≥18 years 2. Clinical diagnosis of stroke Platform Exclusion Criteria: There are no platform level exclusion criteria Each state and domain will specify additional inclusion and exclusion criteria in the respective Domain-Specific Registration. Patients who fulfill the overall platform criteria will be assessed for enrollment into each active domain.
Where this trial is running
Sydney, New South Wales and 1 other locations
- The George Institute for Global Health — Sydney, New South Wales, Australia (RECRUITING)
- University of Calgary — Calgary, Alberta, Canada (RECRUITING)
Study contacts
- Principal investigator: Craig Anderson, MD, PhD — The George Institute
- Study coordinator: Xiaoying Chen, PhD
- Email: xchen@georgeinstitute.org.au
- Phone: +61280524549
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Stroke, Adaptive Platform Trial, Blood Pressure, Tenecteplase, Ischaemic stroke, Intracerebral Haemorrhage